Ann: Appendix 4C - quarterly , page-8

I guess the strategy was to volume fill the pipeline (hence significant sales revenue) and build on that. I think you need to remember the company has never published expected targets but more a steady increase in distribution via Frostbland who have distribution and revenue commitments to CDY. In my view, it is too early to cast aspersions but I would be looking for a significant sales uplift in the next quarter especially with the recruitment of a VP with the charter on building growth with the Evolis brand. I would be disappointed if sales weren't plus $1M for a 12 month trading period.